Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Small Molecule Therapeutics

A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity

Sophia Hu, Masumi Ueda, Lindsay Stetson, James Ignatz-Hoover, Stephen Moreton, Amit Chakrabarti, Zhiqiang Xia, Goutam Karan, Marcos de Lima, Mukesh K. Agrawal and David N. Wald
Sophia Hu
1Department of Pathology, Case Western Reserve University, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masumi Ueda
2Department of Hematology and Oncology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsay Stetson
1Department of Pathology, Case Western Reserve University, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Ignatz-Hoover
1Department of Pathology, Case Western Reserve University, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Moreton
1Department of Pathology, Case Western Reserve University, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Chakrabarti
3Invenio Therapeutics Inc., Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiqiang Xia
3Invenio Therapeutics Inc., Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Goutam Karan
3Invenio Therapeutics Inc., Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcos de Lima
2Department of Hematology and Oncology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mukesh K. Agrawal
3Invenio Therapeutics Inc., Cleveland, Ohio.
4MirX Pharmaceuticals, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dnw@case.edu mukeshagarwal@inveniotherapeutics.com
David N. Wald
1Department of Pathology, Case Western Reserve University, Cleveland, Ohio.
3Invenio Therapeutics Inc., Cleveland, Ohio.
5University Hospitals Case Medical Center, Cleveland, Ohio.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dnw@case.edu mukeshagarwal@inveniotherapeutics.com
DOI: 10.1158/1535-7163.MCT-15-0566 Published July 2016
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    GS87 is a highly specific and potent GSK3 inhibitor that induces AML cell differentiation. A, molecular structure of GS87. B, GS87 is a potent GSK3 inhibitor. In vitro kinase assay for GSK3α and GSK3β. C, GS87 leads to extensive AML differentiation as measured by respiratory burst capacity. OCI, HL-60, and NB4 cells were treated with GS87 (30 μmol/L), Li (10 mmol/L), or SB (20 μmol/L) for 72 hours and differentiation capacity was measured using the NBT reduction assay. D, GS87 leads to more effective AML differentiation than other clinically used GSK3 inhibitors. HL-60 cells were treated with GS87 (30 μmol/L), tideglusib (30 μmol/L), or LY-2090314 (30 μmol/L) for 72 hours and differentiation was measured by the NBT assay. **, P < 0.01. NBT, nitrotetrazolium blue.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    GS87 promotes monocytic differentiation of AML cells. A–C, GS87 leads to extensive acute myeloid leukemia (AML) differentiation as measured by immunophenotyping. AML cell lines were treated with GS87 (30 μmol/L or as indicated), Li (10 mmol/L), or SB (20 μmol/L) for 72 hours and cell surface expression of CD11b and CD14 (HL-60 cells) were measured by flow cytometry. **, P < 0.01. D, treatment with GS87 induces morphologic changes consistent with monocytic differentiation in HL-60 cells compared with untreated cells. Cells were stained using Wright–Giemsa stain. Images were taken using the built-in EVOS XL core camera and acquisition software using a 100× oil objective. The arrows indicate representative cells with marked nuclear condensation or vacuoles. The boxed cells are shown expanded to better illustrate the morphology. E, GS87 leads to AML differentiation in primary patient leukemic cells. Primary patient leukemia cells treated with GS87, Li, or SB showed the highest increase in the cell surface expression of CD11b after GS87 treatment.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    GS87 inhibits AML cell proliferation and causes irreversible growth inhibition. A, GS87 impairs AML proliferation. Equal numbers of HL-60, U937, THP-1, and NB4 cells were treated with GS87 (30 μmol/L), Li (10 mmol/L), or SB (20 μmol/L) for 72 hours and the MTT assay was performed. The MTT signal was normalized to the vehicle-treated control. B, GS87 modulates the cell cycle of AML cells. HL-60 cells were treated with GS87, Li, or SB for 24 hours and assessed for cell-cycle status. Representative flow results are shown and the histogram is an average of three independent studies. **, P < 0.01; NS, no significant difference. C, GS87 inhibits colony formation of AML cells but not normal marrow mononuclear cells. OCI, HL-60, and NB4 cells and normal marrow mononuclear cells were treated with GS87 for 72 hours, after which drug was washed away and equal numbers of viable cells were cultured in semisolid soft agar medium for 7 to 10 days. Colony formation of cells was normalized to a vehicle-treated control.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    GS87 effectively modulates GSK3-dependent proteins. A, GS87-induced differentiation is independent of β-catenin. OCI cells with stable knockdown of β-catenin showed similar differentiation as compared with cells transfected with empty vector after treatment with GS87 for 3 days as measured by NBT reduction. **, P < 0.01. B and C, GS87 modulates GSK3 target proteins important in cell proliferation and differentiation more effectively than Li and SB. HL-60 cells were treated as indicated for 2 and 4 days (B) or 4 days (C) and assessed by Western blot analysis for key AML growth and differentiation proteins that can be modulated by GSK3. NBT, nitrotetrazolium blue.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    GS87-induced AML differentiation is dependent on MAPK signaling. A, comparison of GSK3 inhibitor modulation of gene expression in AML cells. HL-60 cells were treated for 48 hours and the expression of the indicated genes was assessed. Venn diagram of significantly regulated genes (left); validation of microarray results by real-time PCR (right). B, multiple components of the MAPK signaling cascade are activated by GS87 treatment. HL-60 cells were treated with GS87, Li, or SB and the activation of p38, ERK, and JNK were analyzed by Western blot analysis at various time points using phospho-specific antibodies. C, chemical inhibition of ERK (PD08959 10 μmol/L) abrogates the differentiation capacity of GS87 in HL-60 cells. **, P < 0.01.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    GS87 demonstrates efficacy in a circulating AML mouse model system. A, mice treated with GS87 showed longer survival compared with those treated with vehicle or the standard AML therapeutic cytarabine in a mouse model of human primary AML. B, bone marrow blast percentage in mice with primary human AML sacrificed because of moribund state or at study endpoint of 90 days showed significantly higher percentage of blasts in the vehicle and cytarabine groups compared with the GS87 group. Note: the GS87 mice tested were the surviving mice at the end of the study period. C and D, mouse model of circulating HL-60 cells showing a reduced disease burden in the bone marrow (C) and evidence of AML differentiation (D) in the GS87-treated mice.

Tables

  • Figures
  • Additional Files
  • Table 1.

    List of upstream regulators related to MAPK signaling identified from pathway analysis of genes significantly modulated (>2-fold) after treatment with GS87 (30 μmol/L), Li (10 mmol/L), or SB (20 μmol/L) for 48 hours

    Upstream regulatorActivation fold changeP
    MAPK pathway—GS87
    SB203580−5.845.43E−13
    PD98059−5.2317.30E−26
    U0126−4.7545.18E−15
    SP600125−3.8851.92E−09
    SB202190−3.0241.36E−10
    MAPK102.1971.37E−04
    MAPK2.2876.33E−09
    MAP2K1/22.3656.66E−09
    MAPK132.4044.15E−04
    MAPK122.4182.17E−04
    MAP3K72.4941.23E−06
    MAP2K32.7601.10E−05
    MAPK72.7682.01E−05
    MAPK33.0561.45E−06
    MAP2K13.0924.83E−10
    MAPK143.4298.35E−04
    MAP3K83.7652.11E−06
    ERK1/23.8058.31E−11
    ERK3.9618.06E−17
    JNK3.9667.79E−07
    MAPK pathway—SB
    U0126−2.9499.97E−07
    LY294002−2.6816.23E−05
    PD98059−2.6622.13E−05
    SB203580−2.1532.32E−04
    ERK2.0001.70E−05
    MAPK pathway—Li
    JNK2.2214.88E−03
    ERK2.5923.47E−04

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    • Supplementary Figure Legends - Supplementary Figure Legends
    • Supplementary Figure 1 - GS87 does not significantly impact the viability of AML cells
    • Supplementary Figure 2 - Representative flow histograms showing CD11b staining of AML cells after GS87 treatment
    • Supplementary Figure 3 - ATRA leads to marked induction of CD11b in Acute Promyelocytic Cells
    • Supplementary Figure 4 - GS87 does not lead to observable alterations in normal hematopoiesis
    • Supplementary Figure 5 - Heatmap of Z-scores of genes that are significantly dysregulated
    • Supplementary Figure 6 - Heatmap of Z-scores of genes that are significantly dysregulated
    • Supplementary Table 1 - Primer sequences
    • Supplementary Table 2 - Kinase profiling
    • Supplementary Table 3 - Microarray differential expression
    • Supplementary Table 4 - Microarray gene overlap
    • Supplementary Table 5 - Microarray pathway analysis
PreviousNext
Back to top
Molecular Cancer Therapeutics: 15 (7)
July 2016
Volume 15, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Sophia Hu, Masumi Ueda, Lindsay Stetson, James Ignatz-Hoover, Stephen Moreton, Amit Chakrabarti, Zhiqiang Xia, Goutam Karan, Marcos de Lima, Mukesh K. Agrawal and David N. Wald
Mol Cancer Ther July 1 2016 (15) (7) 1485-1494; DOI: 10.1158/1535-7163.MCT-15-0566

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Sophia Hu, Masumi Ueda, Lindsay Stetson, James Ignatz-Hoover, Stephen Moreton, Amit Chakrabarti, Zhiqiang Xia, Goutam Karan, Marcos de Lima, Mukesh K. Agrawal and David N. Wald
Mol Cancer Ther July 1 2016 (15) (7) 1485-1494; DOI: 10.1158/1535-7163.MCT-15-0566
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Efficacy of Rigosertib in Rhabdomyosarcoma and Neuroblastoma
  • Combination of AZD0364 and Selumetinib in KRAS-Mutant NSCLC
  • eFT226, a Selective Inhibitor of eIF4A-Mediated Translation
Show more Small Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement